8-KMaterial AgreementsFinancial EventsSecurities & Listing+1

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Sep 16, 2022)

Filed September 16, 2022For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced on September 16, 2022, the successful pricing and closing of a $1.035 billion offering of 1.00% Convertible Senior Notes due 2027. This financing activity significantly impacts the company's capital structure and future financial flexibility. The net proceeds are being utilized for a combination of strategic debt repayment and mitigating potential equity dilution. A substantial portion of the proceeds, approximately $762.0 million, was used to repay and terminate an existing credit agreement. This deleveraging move strengthens the balance sheet and reduces interest expenses. Concurrently, the company entered into capped call transactions, costing approximately $118.6 million, designed to offset potential dilution to common stockholders upon conversion of the new notes. This structure aims to protect shareholder value while enabling the company to access capital through convertible debt.

Key Highlights

  • 1Alnylam priced $1.035 billion in 1.00% Convertible Senior Notes due 2027.
  • 2The offering included an exercise of the over-allotment option by initial purchasers.
  • 3Proceeds were used to repay and terminate a $762.0 million credit agreement, strengthening the balance sheet.
  • 4Capped call transactions were entered into for approximately $118.6 million to mitigate dilution from note conversions.
  • 5The notes are senior unsecured obligations with a maturity date of September 15, 2027.
  • 6The initial conversion price is approximately $286.20 per share, representing a ~35% premium to the stock price on September 12, 2022.
  • 7The company has the option to redeem the notes starting September 20, 2025, under specific conditions.

Frequently Asked Questions

The primary purpose of the offering was to raise capital, strengthen the company's balance sheet by repaying existing debt, and to put in place mechanisms (capped call transactions) to mitigate potential dilution to existing shareholders when the notes are converted into common stock.

The proceeds were primarily used to repay approximately $762.0 million of borrowings under a credit agreement and to fund the $118.6 million cost of the associated capped call transactions. The remainder of the proceeds will be used for general corporate purposes.

The initial conversion price is approximately $286.20 per share. This represents a premium of about 35.0% over the last reported sale price of Alnylam's common stock ($212.00) on September 12, 2022, indicating the company issued debt convertible at a price significantly higher than its then-current market price.

Capped call transactions are derivative contracts designed to offset potential dilution to the company's common stock that could arise from the conversion of the convertible notes. They also help to reduce the potential cash outlay if the company has to pay more than the principal amount upon conversion. These transactions are capped at a stock price of $424.00 per share.